Navigation Links
Cepheid Reports Second Quarter Revenue of $42.1 Million
Date:7/24/2008

entions, beliefs, expectations and strategies for the future, including those relating to potential growth in clinical product sales, future revenues and gross margin and demand for certain products, future net income and other future operating results. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or level of testing for MRSA and other HAIs; the mix of products sold, which can affect gross margins; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional licenses for new tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's ability to continue to realize manufacturing efficiencies, which are an important factor in improving gross margins; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; the impact of acquisitions; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Ann
'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... METTLER TOLEDO is pleased to ... device CNS110 ScanTape™ . Replacing a traditional ... greater ease and accuracy for transport and logistics ... enhance productivity—an important benefit for load planning and ... profits. , Usable at any point in ...
(Date:9/22/2014)... , Sept. 22, 2014  Spherix Incorporated (SPEX) -- an ... of intellectual property, today announced that the United States Patent ... Company in the month of September that is part of ... issued patent is: USRE45,121 , Application number: US ... Filing date: Dec 27, 2012 The listed ...
(Date:9/21/2014)... first time, scientists have discovered how to produce ultra-thin ... stiffness greater than that of today,s strongest nanotubes and ... team led by John V. Badding, a professor of ... the 21 September 2014 issue of the journal ... view, our discovery is intriguing because the threads we ...
(Date:9/20/2014)... and PITTSFIELD, Massachusetts, USA (PRWEB) September 20, 2014 ... for the prestigious 2015 Prism Awards for Photonics ... product inventions from the multi-billion dollar optics and photonics ... society for optics and photonics , and Photonics ... as well as the versatility of photonics, said SPIE ...
Breaking Biology Technology:ScanTape™ Handheld Dimensioner Increases Processing Volume 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4
... BEIJING , July 6 /PRNewswire-Asia-FirstCall/ ... the development, assembly, marketing and,sale of medical devices and homecare medical products ... sell 10,000 oxygen-chip units to,Beijing C&D Co., Ltd. for RMB11 million ... , , ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
... ROCKVILLE, Md. , July 6 Novavax, Inc. ... Gregory Glenn , M.D., as the company,s Chief Scientific Officer ... and Chief Executive Officer of Novavax.  Previously, Dr. Glenn was ... an associate in international health at Johns Hopkins University,s ...
Cached Biology Technology:Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 3Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 4Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:9/21/2014)... of children with autism are significantly less likely to ... than the mothers of children who are developing normally, ... Institute has found. , Low iron intake was associated ... child if the mother was 35 or older at ... suffered from metabolic conditions such as obesity hypertension or ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Immune system of newborn babies is stronger than previously thought 2
... Biological Sciences Research Council (BBSRC)-led Integrated Biorefining Research and ... which could be used to make biofuel production more ... Issue of the American Chemical Society journal Biochemistry ... the Universities of Warwick and British Columbia, could make ...
... Carolina State University have developed a new technique ... a computer,s ability to build computer models of ... algorithms used to build models of biological systems ... can account for uncertainty and biological variation. This ...
... Institute has won a four-year, $1.9 million grant from ... parasite that causes malaria, laying the groundwork to develop ... "Many antimalarial drugs alleviate symptoms, but do ... malaria parasites are able to persist asymptomatically in the ...
Cached Biology News:First wood-digesting enzyme found in bacteria could boost biofuel production 2New parallelization technique boosts our ability to model biological systems 2Scripps Research scientist wins $1.9 million grant to study malaria 2
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
...
... stains tumor cells of embryonal carcinoma of testis ... cell tumors like seminoma. Glandular epithelium of yolk ... and endocrine cells of stomach and acini cells ... positive. Epitope: Carbohydrate portion on human ...
Ras-related C3 botulinum toxin substrate 1...
Biology Products: